Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825973 | 0.84 | AOC3 (0.50) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| Hydrogen Peroxide SCHEMBL27283588 | 0.81 | AOC3 (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL10738648 | 0.81 | TAAR1 (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL3886956 | 0.77 | AOC3 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL5329951 | 0.76 | SLC7A5 (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL15222220 | 0.75 | ADRA2C (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL8094329 | 0.75 | AOC3 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL21789841 | 0.75 | ADRA2C (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL17084095 | 0.75 | ADRA2C (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL7528534 | 0.75 | TAAR1 (0.46) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | ADRA2A 3818/4885ADRA2C 3380/4885LMNA 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.